complement factor H related 1Genealiases: CFHL · CFHL1 · CFHL1P · CFHR1P · FHL-1 · FHR-1
Q-omics provides the consensus-scored CFHR1 profile across patient tissues and cancer cell-line models. CFHR1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CFHR1 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, CFHR1 protein abundance shows 13,746 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, KIRC, and GBM as cancer lineages where CFHR1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFHR1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFHR1 survival associations across molecular data types. CFHR1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFHR1 RNA expression–survival associations across cancer types. High CFHR1 expression shows unfavorable associations in HNSC, MESO, KIRC, STAD and UVM, but favorable associations in LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CFHR1 RNA expression.
This table summarizes CFHR1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CFHR1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFHR1 shows lower tumor expression in KIRC, BRCA, CHOL, KICH, KIRP and COAD. The KIRC box plot shows higher CFHR1 RNA expression in normal versus tumor tissue (log2 FC = −0.727, t-test p < 0.001).
This table shows molecular features associated with CFHR1 in patient tissues and cancer cell lines. In patient samples, CFHR1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CFHR1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
